Tramadol Hydrochloride + Dexketoprofen
Skudexa contains tramadol hydrochloride and dexketoprofen as active substances.
Tramadol hydrochloride is a pain reliever belonging to the group of medicines called opioids, which act on the central nervous system.
It relieves pain by acting on specific nerve cells in the brain and spinal cord.
Dexketoprofen is a pain reliever belonging to the group of medicines called nonsteroidal anti-inflammatory drugs (NSAIDs).
Skudexa is used for the symptomatic short-term treatment of moderate to severe acute pain in adults.
Before starting treatment with Skudexa, discuss the following with your doctor:
Tramadol may lead to physical and psychological dependence. If the medication is taken for a long time, its effect may weaken, and higher doses may be needed (development of tolerance). In patients with a tendency to abuse medications or those dependent on medications, treatment with Skudexa should be short-term and under close medical supervision.
Tell your doctor if any of these problems occur during treatment with Skudexa or have occurred in the past.
If you experience any of the following symptoms while taking Skudexa, tell your doctor: excessive fatigue, loss of appetite, severe abdominal pain, nausea, vomiting, or low blood pressure. This may indicate that you have adrenal insufficiency (low cortisol levels). If such symptoms occur, consult your doctor, who will decide whether you need hormone replacement therapy.
Tramadol is metabolized in the liver by an enzyme. In some people, there is a certain variant of this enzyme, which can have different effects. In some people, pain relief may not be sufficient, and in others, the risk of serious side effects may be higher.
Stop taking the medication and consult your doctor immediately if you experience any of the following side effects: slowed breathing or shallow breathing, confusion, drowsiness, pinpoint pupils, nausea, or vomiting, constipation, loss of appetite.
After taking tramadol in combination with certain antidepressants or tramadol alone, there is a small risk of serotonin syndrome. If you experience any symptoms of this syndrome with a severe course, seek medical attention immediately (see section 4 "Possible Side Effects").
Skudexa may cause respiratory depression during sleep, such as sleep apnea (pauses in breathing during sleep) and sleep-related hypoxemia (low oxygen levels in the blood) .
Symptoms may include pauses in breathing during sleep, nighttime awakenings due to shortness of breath, difficulty maintaining sleep, or excessive daytime sleepiness. If you or someone else observes these symptoms, consult your doctor. Your doctor may recommend reducing the dose.
Skudexa may mask the symptoms of infection, such as fever and pain. As a result, Skudexa may delay the application of appropriate infection treatment and consequently lead to increased risk of complications. This has been observed in bacterial pneumonia and bacterial skin infections associated with chickenpox. If you are taking this medication during an infection, and the symptoms of the infection persist or worsen, consult your doctor immediately.
Avoid taking this medication during chickenpox.
This medication has not been studied in children and adolescents. The safety and efficacy of this medication have not been established, and therefore, it should not be used in children and adolescents.
Use in children with respiratory disorders
Tramadol is not recommended in children with respiratory disorders, as the symptoms of tramadol toxicity may be exacerbated in them.
Tell your doctor about all the medications you are currently taking or have recently taken, as well as any medications you plan to take, including those available without a prescription.
Certain medications should not be taken at the same time as Skudexa, and for others, the dose may need to be changed due to concurrent use of Skudexa.
Always inform your doctor if you are taking any of the following medications with Skudexa:
Concomitant use not recommended:
Concomitant use requiring caution:
Concomitant use requiring special consideration:
The pain-relieving effect of tramadol may be reduced, and the duration of action may be shortened when you are also taking:
The risk of side effects increases:
Do not drink alcohol while taking Skudexa, as it may enhance the effect of the medication.
Instructions for taking Skudexa - see section 3.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a baby, ask your doctor for advice before taking this medication.
Dexketoprofen may cause kidney and heart problems in the unborn baby.
This medication may increase the risk of bleeding in you and your baby and may cause delayed or prolonged labor.
From the 20th week of pregnancy, dexketoprofen may cause:
Tramadol is excreted into breast milk.
Taking Skudexa is contraindicated during pregnancy and breastfeeding.
Skudexa may affect your ability to drive and use machines, due to the possibility of dizziness, vision disturbances, or drowsiness as side effects during treatment.
This is especially true when Skudexa is taken with medications that affect mood and emotions or with alcohol.
If you experience such symptoms, do not drive vehicles or operate machinery until the symptoms have resolved.
Skudexa contains 2.7 g of sucrose per dose. This should be taken into account in patients with diabetes.
If your doctor has informed you that you have an intolerance to some sugars, consult your doctor before taking the medication.
Always take this medication exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
Use the smallest effective dose for the shortest duration necessary to relieve the symptoms. If the symptoms of the infection (such as fever and pain) persist or worsen, consult your doctor immediately (see section 2).
The dose of Skudexa will depend on the type, severity, and duration of the pain.
Your doctor will tell you how many sachets to take per day and for how long.
The recommended daily dose is usually 1 sachet (corresponding to 75 mg tramadol hydrochloride and 25 mg dexketoprofen) every 8 hours, with no more than 3 sachets per day (corresponding to 225 mg tramadol hydrochloride and 75 mg dexketoprofen), and treatment should not last longer than 5 days.
Skudexa should not be used in children and adolescents.
In patients aged 75 or older, your doctor may recommend longer intervals between doses, as the body may metabolize the medication more slowly.
Patients with severe liver and/or kidney disease should not take Skudexa.
In case of kidney function disorders, if you have mild kidney failure, your doctor may recommend prolonging the interval between doses.
In case of liver function disorders, if you have mild or moderate liver failure, your doctor may recommend prolonging the interval between doses.
The contents of the sachet should be dissolved in a glass of water, mixed well to facilitate dissolution.
The resulting solution should be drunk immediately after preparation.
Food delays the absorption of Skudexa, so to achieve a faster effect, take the granules for oral solution in sachets at least 30 minutes before a meal.
If you have taken more than the recommended dose of Skudexa, inform your doctor or go to the emergency department of the nearest hospital immediately. Remember to take the package or patient information leaflet with you.
Symptoms of overdose are:
Do not take a double dose to make up for a missed dose. The next dose should be taken according to the dosing schedule (see section 3 "How to Take Skudexa").
It is unlikely that you will experience any effects from stopping Skudexa treatment.
However, in rare cases, patients who have taken Skudexa for some time may feel unwell if treatment is stopped abruptly. They may feel agitated, anxious, nervous, or unsure, feel confused, overexcited, have sleep problems, and have stomach or intestinal disorders. Rarely, patients may experience panic attacks, hallucinations, delusions, paranoia, or loss of identity. They may experience unusual sensations, such as itching, tingling, numbness, and ringing in the ears. Further unusual symptoms, such as confusion, delusions, depersonalization, and changes in perception of reality (derealization) and persecutory delusions (paranoia), have been observed very rarely. If you experience any of these symptoms after stopping Skudexa treatment, consult your doctor.
If you have any further questions about taking this medication, ask your doctor.
Like all medicines, Skudexa can cause side effects, although not everybody gets them.
Possible side effects are listed below and are grouped by frequency of occurrence.
Inform your doctor immediately if you experience symptoms of an allergic reaction, such as swelling of the face, tongue, and/or throat, and/or difficulty swallowing or hives with breathing difficulties.
Stop taking Skudexa as soon as possible if you notice the appearance of a rash or any changes in the mouth or mucous membranes or any signs of allergy.
Very Common Side Effects(may affect more than 1 in 10 people):
Common Side Effects(may affect up to 1 in 10 people):
Uncommon Side Effects(may affect up to 1 in 100 people):
Rare Side Effects(may affect up to 1 in 1,000 people):
The medication may cause psychological disturbances. Their intensity and nature may vary (depending on the patient's personality and the duration of treatment) and include:
Asthma has been reported to worsen.
Upon sudden discontinuation of treatment, withdrawal symptoms may occur (see "Stopping Skudexa Treatment").
Seizures have occurred mainly after administration of high doses of tramadol or when tramadol was used at the same time as other medications that can cause seizures.
Very Rare Side Effects(may affect up to 1 in 10,000 people):
Frequency Not Known(frequency cannot be estimated from the available data):
Tell your doctor if you notice any side effects, including those not listed in this leaflet, or if you experience any side effects not listed in this leaflet.
The most common side effects during treatment with Skudexa are nausea and dizziness, which occur in more than 1 in 10 patients.
When taking nonsteroidal anti-inflammatory medications, fluid retention and swelling (especially of the ankles and feet) may occur, as well as increased blood pressure and heart failure.
Taking medications like Skudexa may be associated with a slight increase in the risk of heart attack ("myocardial infarction") or stroke.
In patients with immune system disorders affecting connective tissue (systemic lupus erythematosus or mixed connective tissue disease), taking anti-inflammatory medications may rarely cause fever, headache, and stiffness of the neck/cervical spine.
If you experience any side effects, including those not listed in this leaflet, please inform your doctor or pharmacist.
Side effects can be reported directly to the Department of Post-Marketing Surveillance of Medicinal Products, Medical Devices, and Biocidal Products:
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of the medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiry date stated on the carton and sachet after "EXP". The expiry date refers to the last day of the month.
There are no special storage temperature requirements.
Store in the original package to protect from light.
Medications should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medications that are no longer needed. This will help protect the environment.
White to almost white granules for oral solution, available in heat-sealed sachets made of multilayer foil Paper/Aluminum/PE (in the form of a vinyl acetate copolymer) in a cardboard box.
Packages contain 2, 3, 10, 15, 20, 50, 100, and 500 sachets.
Not all pack sizes may be marketed.
Menarini International Operations Luxembourg S.A.
1, Avenue de la Gare
1611 Luxembourg
Luxembourg
E-Pharma Trento S.p.A.
Frazione Ravina – Via Provina, 2
38123 Trento (TN)
Italy
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, Greece, Hungary, Ireland, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, United Kingdom (Northern Ireland): Skudexa
France: Skudexum
Italy: Lenizak
Spain: Enanplus
Date of last revision of the leaflet: 12/2022
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.